Stock Events

Stock Events

Kazia Therapeutics Limited 

$13.41
35
-$0.27-1.94% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
13.34
Day Low
13.33
52W High
17.4
52W Low
4.86
Volume
3,034
Avg. Volume
-
Mkt Cap
153.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28FebExpected
Q1 2021
Q2 2021
Q2 2021
Q3 2021
Q4 2021
Q4 2021
Q4 2023
-0.01
-0
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-47,809.55%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
27,622.14Revenue
-13.21MNet Income

Analyst Ratings

29.33Average Price Target
The highest estimate is 34.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KZIA. It's not an investment recommendation.
Apple
9
AAPL
Tesla
9
TSLA
Alphabet
8
GOOGL
Microsoft
7
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap2B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, competing with Kazia in the cancer metabolism space.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation works on small molecule drugs for oncology, putting it in direct competition with Kazia's therapeutic development.
Exelixis
EXEL
Mkt Cap12.7B
Exelixis, Inc. is involved in developing and commercializing new medicines for difficult-to-treat cancers, making it a competitor in the oncology market.
Array Technologies
ARRY
Mkt Cap777.74M
Array BioPharma specializes in the development of targeted small molecule drugs to treat cancer, directly competing with Kazia's focus.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of therapeutic areas including those targeted by Kazia.

About

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Show more...
CEO
John Friend
Employees
6
Country
Australia
ISIN
US48669G3039

Listings

STU
DE
NV9N.STU
STU
DE
NV9.STU
MU
DE
NV9M.MU
XNAS
US
KZIA

0 Comments

Share your thoughts

FAQ

What is Kazia Therapeutics Limited stock price today?▼
The current price of KZIA is $13.41 USD — it has decreased by -1.94% in the past 24 hours. Watch Kazia Therapeutics Limited stock price performance more closely on the chart.
What is Kazia Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kazia Therapeutics Limited stocks are traded under the ticker KZIA.
Is Kazia Therapeutics Limited stock price growing?▼
KZIA stock has fallen by -0.85% compared to the previous week, the month change is a -8.18% fall, over the last year Kazia Therapeutics Limited has showed a +73.87% increase.
What is Kazia Therapeutics Limited market cap?▼
Today Kazia Therapeutics Limited has the market capitalization of 153.18M
What is Kazia Therapeutics Limited revenue for the last year?▼
Kazia Therapeutics Limited revenue for the last year amounts to 27,622.14 USD.
What is Kazia Therapeutics Limited net income for the last year?▼
KZIA net income for the last year is -13.21M USD.
How many employees does Kazia Therapeutics Limited have?▼
As of August 22, 2026, the company has 6 employees.
In which sector is Kazia Therapeutics Limited located?▼
Kazia Therapeutics Limited operates in the Health & Wellness sector.
When did Kazia Therapeutics Limited complete a stock split?▼
The last stock split for Kazia Therapeutics Limited was on April 17, 2025 with a ratio of 1:5.
Where is Kazia Therapeutics Limited headquartered?▼
Kazia Therapeutics Limited is headquartered in NEW SOUTH WALES 2113, Australia.